You are here: Industry Insights > CPI-613

News List

Rafael Pharmaceuticals Receives Fast Track Designation for CPI-613 americanpharmaceuticalreview
November 23, 2020
Rafael Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s lead compound, CPI-613® (devimistat), for the treatment of metastatic pancreatic cancer.
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613 americanpharmaceuticalreview
November 11, 2020
Rafael Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for CPI-613® (devimistat) for the treatment of soft tissue sarcoma.
Rafael Expands CPI-613 Trial americanpharmaceuticalreview
December 27, 2019
Rafael Pharmaceuticals announced the expansion of its Phase 2 clinical trial of CPI-613® (devimistat) for patients with relapsed or refractory Burkitt’s lymphoma/leukemia.
Rafael Pharma Signs License Agreement with Ono Pharmaceutical contractpharma
June 26, 2019
Aims to accelerate development and commercialization of cancer drug candidate CPI-613 (devimistat) in Japan and other Asian countries.